Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Biree Andemariam, Timothy Mant, Perla Eleftheriou, Sanne Lugthart, Lanetta Bronté-Hall, Filipa Barroso, Gershwin Blyden, James Mason, Constance M Barysauskas, Joseph Yen, Karen Tang, Rahul Ballal, Kenneth Attie

Blood (2021) 138 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2021-149536

Published: 2021

Journal Articles

PDE9 Inhibition By IMR-687 Improves Markers of Beta-Thalassemia in the Hbb th1/th1 Experimental Mouse Model

Thiago Trovati Maciel, Caroline Carvalho, Rachel Rignault, Slimane Allali, Biree Andemariam, Jennifer Isler OCain, Rahul Ballal

Blood (2021) 138 (Supplement 1): 945.

https://doi.org/10.1182/blood-2021-149481

Published: 2021

Journal Articles

IMR-261, a Novel Oral Nrf2 Activator, Induces Fetal Hemoglobin in Human Erythroblasts, Reduces VOCs, and Ameliorates Ineffective Erythropoiesis in Experimental Mouse Models of Sickle Cell Disease and Beta-Thalassemia

Thiago Trovati Maciel, Caroline Carvalho, Rachel Rignault, Biree Andemariam, Betty S. Pace, Jennifer Isler OCain, Rahul Ballal

Blood (2021) 138 (Supplement 1): 853.

https://doi.org/10.1182/blood-2021-149528

Published: 2021

Journal Articles

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Lanetta Bronte-Hall, MD MPH, MSPH, Biree Andemariam, MD, Blyden Gershwin, MD, Sanne Lugthart, MD PhD, Timothy Mant, MB, FFPM, FRCP, Jo Howard, MBBChir, MRCP, FRCPath, Henry Fok, MBBS, PhD, Perla Eleftheriou, FRCPath, MRCP, Robert Ward Hagar, MD, James Mason, DO, Rahul Ballal, PhD, Joelle Lufkin, MPH, Eleanor Lisbon, MD MPH

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140540

Published: 2020

Journal Articles

Patient-Related Outcomes of Elective Major Orthopedic Surgery in Severe Hemophilia Patients: A Review of the Literature and a Proposed Agenda for Research.

Marc F. Botteman, MSc, Rahul Ballal, Ashish V. Joshi, PhD

Blood (2007) 110 (11): 965.

https://doi.org/10.1182/blood.V110.11.965.965

Published: 2007

NARROW

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

PDE9 Inhibition By IMR-687 Improves Markers of Beta-Thalassemia in the Hbb th1/th1 Experimental Mouse Model

IMR-261, a Novel Oral Nrf2 Activator, Induces Fetal Hemoglobin in Human Erythroblasts, Reduces VOCs, and Ameliorates Ineffective Erythropoiesis in Experimental Mouse Models of Sickle Cell Disease and Beta-Thalassemia

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Patient-Related Outcomes of Elective Major Orthopedic Surgery in Severe Hemophilia Patients: A Review of the Literature and a Proposed Agenda for Research.

Email alerts

ASH Publications

American Society of Hematology

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

PDE9 Inhibition By IMR-687 Improves Markers of Beta-Thalassemia in the Hbb th1/th1 Experimental Mouse Model

IMR-261, a Novel Oral Nrf2 Activator, Induces Fetal Hemoglobin in Human Erythroblasts, Reduces VOCs, and Ameliorates Ineffective Erythropoiesis in Experimental Mouse Models of Sickle Cell Disease and Beta-Thalassemia

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Patient-Related Outcomes of Elective Major Orthopedic Surgery in Severe Hemophilia Patients: A Review of the Literature and a Proposed Agenda for Research.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only